cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.sufentanilsufentanil and trimipramine both increase sedation. Use Caution/Monitor.sufentanil SLsufentanil SL, trimipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.sulfamethoxazoletrimipramine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.sumatriptansumatriptan and trimipramine both increase serotonin levels. Modify Therapy/Monitor Closely.sumatriptan intranasalsumatriptan intranasal and trimipramine both increase serotonin levels. Modify Therapy/Monitor Closely.suvorexantsuvorexant and trimipramine both increase sedation. Modify Therapy/Monitor Closely. Dosage adjustments of suvorexant and concomitant CNS depressants may be necessarytacrolimustacrolimus and trimipramine both increase QTc interval. Use Caution/Monitor.tapentadoltapentadol and trimipramine both increase sedation. Use Caution/Monitor.trimipramine and tapentadol both increase serotonin levels. Modify Therapy/Monitor Closely.tecovirimattecovirimat will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Tecovirimat is a weak inhibitor of CYP2C8 and CYP2C19. Monitor for adverse effects if coadministered with sensitive substrates of these enzymes.tecovirimat will decrease the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered.telavancintrimipramine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.temazepamtemazepam and trimipramine both increase sedation. Use Caution/Monitor.terbinafineterbinafine will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Assess need to reduce dose of CYP2D6-metabolized drug.terbutalinetrimipramine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.tetrabenazinetetrabenazine and trimipramine both increase QTc interval. Use Caution/Monitor.thioridazinethioridazine and trimipramine both increase sedation. Use Caution/Monitor.thiothixenethiothixene and trimipramine both increase sedation. Use Caution/Monitor.thyroid desiccatedthyroid desiccated increases effects of trimipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.tiotropiumtiotropium and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.tolterodinetolterodine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.topiramatetrimipramine and topiramate both increase sedation. Modify Therapy/Monitor Closely.tramadoltramadol and trimipramine both increase sedation. Use Caution/Monitor.trimipramine and tramadol both increase serotonin levels. Modify Therapy/Monitor Closely.trazodonetrazodone and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.trazodone and trimipramine both increase sedation. Use Caution/Monitor.triazolamtriazolam and trimipramine both increase sedation. Use Caution/Monitor.triclabendazoletriclabendazole will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole. triclofostriclofos and trimipramine both increase sedation. Use Caution/Monitor.trifluoperazinetrifluoperazine and trimipramine both increase sedation. Use Caution/Monitor.trihexyphenidyltrihexyphenidyl and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.trimethoprimtrimipramine and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.triprolidinetriprolidine and trimipramine both increase sedation. Use Caution/Monitor.tropisetrontrimipramine and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.trospium chloridetrospium chloride and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.valbenazinevalbenazine and trimipramine both increase QTc interval. Use Caution/Monitor.valerianvalerian and trimipramine both increase sedation. Use Caution/Monitor.vecuroniumvecuronium and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.venlafaxinetrimipramine and venlafaxine both increase QTc interval. Modify Therapy/Monitor Closely.voclosporinvoclosporin, trimipramine. Either increases effects of the other by QTc interval. Use Caution/Monitor.voriconazoletrimipramine and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.voriconazole will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.xylometazolinetrimipramine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.yohimbinetrimipramine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.ziconotidetrimipramine and ziconotide both increase sedation. Use Caution/Monitor.ziprasidoneziprasidone and trimipramine both increase sedation. Use Caution/Monitor.zolmitriptanzolmitriptan and trimipramine both increase serotonin levels. Modify Therapy/Monitor Closely.Minor (75)acarbosetrimipramine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.acetazolamideacetazolamide will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.amobarbitalamobarbital, trimipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.anastrozoleanastrozole will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.atropinetrimipramine increases levels of atropine by unknown mechanism. Minor/Significance Unknown.atropine IV/IMtrimipramine increases levels of atropine IV/IM by unknown mechanism. Minor/Significance Unknown.azithromycinazithromycin increases toxicity of trimipramine by QTc interval. Minor/Significance Unknown.bazedoxifene/conjugated estrogensbazedoxifene/conjugated estrogens, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.brimonidinetrimipramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.butabarbitalbutabarbital, trimipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.butalbitalbutalbital, trimipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.carbamazepinecarbamazepine decreases levels of trimipramine by increasing metabolism. Minor/Significance Unknown.chloroquinechloroquine increases toxicity of trimipramine by QTc interval. Minor/Significance Unknown.chlorpromazinetrimipramine, chlorpromazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.trimipramine, chlorpromazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.chlorpropamidetrimipramine increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.conjugated estrogensconjugated estrogens, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.conjugated estrogens, vaginalconjugated estrogens, vaginal, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.cyclophosphamidecyclophosphamide will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.desfluranedesflurane, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.dexmethylphenidatedexmethylphenidate increases effects of trimipramine by decreasing metabolism. Minor/Significance Unknown.estradiolestradiol, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.estrogens conjugated syntheticestrogens conjugated synthetic, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.estrogens esterifiedestrogens esterified, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens may inhibit hepatic metabolism of tricyclic antidepressants. However, interactions are not common.estropipateestropipate, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.ethinylestradiolethinylestradiol, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Oxidative metabolism of TCAs may be decreased by ethinyl estradiol. Increased antidepressant serum concentrations may occur. Potential for increased TCA adverse effects.etomidateetomidate, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.eucalyptustrimipramine and eucalyptus both increase sedation. Minor/Significance Unknown.fluphenazinetrimipramine, fluphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.trimipramine, fluphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.glimepiridetrimipramine increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.glipizidetrimipramine increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.glyburidetrimipramine increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.hydroxyprogesterone caproate (DSC)hydroxyprogesterone caproate (DSC), trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.insulin asparttrimipramine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.insulin detemirtrimipramine increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.insulin glarginetrimipramine increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.insulin glulisinetrimipramine increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.insulin lisprotrimipramine increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.insulin NPHtrimipramine increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.insulin regular humantrimipramine increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.isoproterenolisoproterenol, trimipramine. Mechanism: unknown. Minor/Significance Unknown. Risk of cardiac arrhythmias.ketamineketamine, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.larotrectiniblarotrectinib will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.lithiumlithium, trimipramine. Other (see comment). Minor/Significance Unknown. Comment: Risk of neurotoxicity in geriatric pts. Multiple mechanisms involved.mestranolmestranol, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.metformintrimipramine increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.miglitoltrimipramine increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.nateglinidetrimipramine increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.panax ginsengpanax ginseng increases effects of trimipramine by pharmacodynamic synergism. Minor/Significance Unknown.pentobarbitalpentobarbital, trimipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.perphenazinetrimipramine, perphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.trimipramine, perphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.phenobarbitalphenobarbital, trimipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.pioglitazonetrimipramine increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.pleurisy rootpleurisy root decreases effects of trimipramine by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.primidoneprimidone, trimipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.prochlorperazinetrimipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.trimipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.progesterone micronizedprogesterone micronized, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.promazinetrimipramine, promazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.trimipramine, promazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.promethazinetrimipramine, promethazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.trimipramine, promethazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.propofolpropofol, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.repaglinidetrimipramine increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.rosiglitazonetrimipramine increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.sagetrimipramine and sage both increase sedation. Minor/Significance Unknown.saxagliptintrimipramine increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.serdexmethylphenidate/dexmethylphenidateserdexmethylphenidate/dexmethylphenidate increases effects of trimipramine by decreasing metabolism. Minor/Significance Unknown.sevofluranesevoflurane, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.sitagliptintrimipramine increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.sulfamethoxazolesulfamethoxazole decreases levels of trimipramine by unspecified interaction mechanism. Minor/Significance Unknown.thioridazinetrimipramine, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.trimipramine, thioridazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.tolazamidetrimipramine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.tolbutamidetrimipramine increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.trifluoperazinetrimipramine, trifluoperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.trimipramine, trifluoperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.vasopressintrimipramine increases effects of vasopressin by pharmacodynamic synergism. Minor/Significance Unknown.verapamilverapamil increases levels of trimipramine by decreasing metabolism. Minor/Significance Unknown.vildagliptintrimipramine increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.zolpidemzolpidem, trimipramine. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.5-HTPMonitor Closely (1)trimipramine and 5-HTP both increase serotonin levels. Modify Therapy/Monitor Closely.abametapirSerious - Use Alternative (1)abametapir will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir.abirateroneMonitor Closely (1)abiraterone increases levels of trimipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.abobotulinumtoxinAMonitor Closely (1)abobotulinumtoxinA increases effects of trimipramine by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .acarboseMinor (1)trimipramine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.acetazolamideMinor (1)acetazolamide will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.aclidiniumMonitor Closely (1)aclidinium and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.adagrasibSerious - Use Alternative (1)adagrasib, trimipramine. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring